Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study

Blood Pressure

Volumn 21, Issue 5, 2012, Pages 311-319

  Manner, Ingjerd W ^a,b   Baekken, Morten ^b   Oektedalen, Olav ^b   Os, Ingrid ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anti retroviral agents; Antiretroviral therapy; Cardiovascular risk; HIV infections; Hypertension

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADULT; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84866925739     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2012.680742     Document Type: Article

References (42)

1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increasedacute myocardial infarction rates and cardiovascular risk factorsamong patients with human immunodeficiency virusdisease. J Clin Endocrinol Metab. 2007;92:2506-2512.
2. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, BurtcelB, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
3. Obel N, Thomsen HF, Kronborg G, Larsen CS, HildebrandtPR, Sorensen HT, et al. Ischemic heart disease in HIV-infectedand HIV-uninfected individuals: A population-basedcohort study. Clin Infect Dis. 2007;44:1625-1631.
4. Friis-Moller N, Sabin CA, Weber R, d'A rminio MA, El-SadrWM, Reiss P, et al. Combination antiretroviral therapy andthe risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
5. Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, et al. Longitudinal changes in serum lipids among HIV-infectedmen on highly active antiretroviral therapy. HIV Med. 2007;8:280-287.
6. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects ofprotease inhibitors on hyperglycemia, hyperlipidemia, andlipodystrophy: A 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
7. Kuller LH, Tracy R, Belloso W, De WS, Drummond F, LaneHC, et al. Inflammatory and coagulation biomarkers andmortality in patients with HIV infection. PLoS Med. 2008;5:e203.
8. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactiveprotein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-273.
9. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, BucknerK, Tedaldi EM, et al. Low CD4-T cell count is a risk factorfor cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-447.
10. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and therisk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
11. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, KowalskaJ, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-definingillnesses in Europe. J Acquir Immune Defic Syndr. 2010;55:262-270.
12. Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension inan urban HIV-positive population compared with the generalpopulation: Influence of combination antiretroviral therapy. JHypertens. 2008;26:2126-2133.
13. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, BruunJN. Prevalence of hypertension in HIV-positive patients onhighly active retroviral therapy (HAART) compared withHAART-naive and HIV-negative controls: Results from aNorwegian study of 721 patients. Eur J Clin Microbiol InfectDis. 2003;22:731-736.
14. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, FratinoP, Sacchi P, et al. Hypertension among HIV patients: Prevalenceand relationships to insulin resistance and metabolicsyndrome. J Hypertens. 2003;21:1377-1382.
15. Jerico C, Knobel H, Montero M, Sorli ML, Guelar A, Gimeno JL, et al. Hypertension in HIV-infected patients:Prevalence and related factors. Am J Hypertens. 2005;18:1396-1401.
16. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, RiddlerSA, et al. Association between highly active antiretroviraltherapy and hypertension in a large cohort of men followedfrom 1984 to 2003. AIDS. 2005;19:953-960.
17. Glass TR, Ungsedhapand C, Wolbers M, Weber R, VernazzaPL, Rickenbach M, et al. Prevalence of risk factors for cardiovasculardisease in HIV-infected patients over time: TheSwiss HIV Cohort Study. HIV Med. 2006;7:404-410.
18. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviralmedications associated with elevated blood pressure amongpatients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019-1026.
19. Palacios R, Santos J, Garcia A, Castells E, Gonzalez M, RuizJ, et al. Impact of highly active antiretroviral therapy on bloodpressure in HIV-infected patients. A prospective study in acohort of naive patients. HIV Medicine. 2006;7:10-15.
20. Chow DC, Souza SA, Chen R, Richmond-Crum SM, GrandinettiA, Shikuma C. Elevated blood pressure in HIV-infectedindividuals receiving highly active antiretroviral therapy. HIVClin Trials. 2003;4:411-416.
21. Thiebaut R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, Monforte AD, et al. Predictors of hypertension andchanges of blood pressure in HIV-infected patients. AntivirTher. 2005;10:811-823.
22. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, GermanoG, et al. 2007 Guidelines for the Management of ArterialHypertension: The Task Force for the Management ofArterial Hypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, III, Feldman HI, et al. A new equation to estimate glomerularfiltration rate. Ann Intern Med. 2009;150:604-612.
24. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular diseaseprevention in clinical practice: Full text. Fourth JointTask Force of the European Society of Cardiology and othersocieties on cardiovascular disease prevention in clinical practice(constituted by representatives of nine societies and byinvited experts). Eur J Cardiovasc Prev Rehabil. 2007;14Suppl 2:S1-S113.
25. Westheim A, Klemetsrud T, Tretli S, Stokke HP, Olsen H. Blood pressure levels in treated hypertensive patients in generalpractice in Norway. Blood Press. 2001;10:37-42.
26. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolledhypertension across Europe: The Global CardiometabolicRisk Profile in Patients with hypertension disease survey. JHypertens. 2008;26:2064-2070.
27. Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, et al. Leptin, not adiponectin, predicts hypertensionin the Copenhagen City Heart Study. Am J Hypertens. 2010;23:327-333.
28. Bombelli M, Facchetti R, Sega R, Carugo S, Fodri D, BrambillaG, et al. Impact of body mass index and waist circumferenceon the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage. Hypertension. 2011.
29. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changesin relation to urinary sodium excretion. JAMA. 2011;305:1777-1785.
30. Rywik SL, Williams OD, Pajak A, Broda G, Davis CE, Kawalec E, et al. Incidence and correlates of hypertension inthe Atherosclerosis Risk in Communities (ARIC) study andthe Monitoring Trends and Determinants of CardiovascularDisease (POL-MONICA) project. J Hypertens. 2000;18:999-1006.
31. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessmentof frequency of progression to hypertension innon-hypertensive participants in the Framingham HeartStudy: A cohort study. Lancet. 2001;358:1682-166.
32. Jung O, Bickel M, Ditting T, Rickerts V, Welk T, Helm EB, et al. Hypertension in HIV-1-infected patients and its impacton renal and cardiovascular integrity. Nephrol Dial Transplant. 2004;19:2250-2258.
33. Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDSCare (Chic) . 2011.
34. Manner IW, Baekken M, Oektedalen O, Sandvik L, Os I. Effect of HIV duration on ambulatory blood pressure inHIV-infected individuals with high office blood pressure. Blood Press. 2010;19:188-195.
35. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, LampirisH, et al. T cell activation is associated with lower CD4-T cell gains in human immunodeficiency virus-infectedpatients with sustained viral suppression during antiretroviraltherapy. J Infect Dis. 2003;187:1534-1543.
36. Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, LaRA, et al. Markers of inflammation, coagulation, and renalfunction are elevated in adults with HIV infection. J InfectDis. 2010;201:1788-1795.
37. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, RidkerPM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
38. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-140.
39. Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS. 2001;15:805-807.
40. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d ' Arminio MA, et al. Cardiovascular disease risk factors inHIV patients-association with antiretroviral therapy. Resultsfrom the DAD study. AIDS. 2003;17:1179-1193.
41. EACS gulidelines, version 6. Web. 2011 Available from:http://www. europeanaidsclinicalsociety. org/images/stories/EACS-Pdf/eacsguidelines-6. pdf42.
42. Boccara F, Auclair M, Cohen A, Lefevre C, Prot M, Bastard JP, et al. HIV protease inhibitors activate theadipocyte renin angiotensin system. Antivir Ther. 2010;15:363-375.